IMV101
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IMV101, covering 2026-03-30 to 2026-03-30. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [EARLY_Phase 1]